Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
2011 2
2012 1
2014 3
2015 7
2016 1
2017 1
2018 2
2019 3
2020 3
2021 2
2022 4
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma.
Hofman DA, Ruiz-Orera J, Yannuzzi I, Murugesan R, Brown A, Clauser KR, Condurat AL, van Dinter JT, Engels SAG, Goodale A, van der Lugt J, Abid T, Wang L, Zhou KN, Vogelzang J, Ligon KL, Phoenix TN, Roth JA, Root DE, Hubner N, Golub TR, Bandopadhayay P, van Heesch S, Prensner JR. Hofman DA, et al. Among authors: van dinter jt. Mol Cell. 2024 Jan 18;84(2):261-276.e18. doi: 10.1016/j.molcel.2023.12.003. Epub 2024 Jan 3. Mol Cell. 2024. PMID: 38176414 Free article.
Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma.
Hofman DA, Ruiz-Orera J, Yannuzzi I, Murugesan R, Brown A, Clauser KR, Condurat AL, van Dinter JT, Engels SAG, Goodale A, van der Lugt J, Abid T, Wang L, Zhou KN, Vogelzang J, Ligon KL, Phoenix TN, Roth JA, Root DE, Hubner N, Golub TR, Bandopadhayay P, van Heesch S, Prensner JR. Hofman DA, et al. Among authors: van dinter jt. bioRxiv [Preprint]. 2023 May 6:2023.05.04.539399. doi: 10.1101/2023.05.04.539399. bioRxiv. 2023. PMID: 37205492 Free PMC article. Updated. Preprint.
Translational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-Fluorouridine.
Palomar-Siles M, Heldin A, Zhang M, Strandgren C, Yurevych V, van Dinter JT, Engels SAG, Hofman DA, Öhlin S, Meineke B, Bykov VJN, van Heesch S, Wiman KG. Palomar-Siles M, et al. Among authors: van dinter jt. Cell Death Dis. 2022 Nov 25;13(11):997. doi: 10.1038/s41419-022-05431-2. Cell Death Dis. 2022. PMID: 36433934 Free PMC article.
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S, Colombel JF, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S; GARDENIA Study Group. Danese S, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):118-127. doi: 10.1016/S2468-1253(21)00294-6. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798038 Free article. Clinical Trial.
Submucosal Injection of the RNA Oligonucleotide GUT-1 in Active Ulcerative Colitis Patients: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Induction Trial.
Atreya R, Kühbacher T, Waldner MJ, Hirschmann S, Drvarov O, Abu Hashem R, Maaser C, Kucharzik T, Dinter J, Mertens J, Schramm C, Holler B, Mössner J, Suzuki K, Yokoyama J, Terai S, Uter W, Yoneyama H, Asakura H, Hibi T, Neurath MF. Atreya R, et al. Among authors: dinter j. J Crohns Colitis. 2024 Mar 1;18(3):406-415. doi: 10.1093/ecco-jcc/jjad162. J Crohns Colitis. 2024. PMID: 37777210 Clinical Trial.
35 results